By Rosie Wilson
ATX-101 is an experimental injection that seeks to reduce the appearance of a double chin.
California based medical company Kythera Biopharmaceuticals have developed the drug, which is intended to be administered in a series of treatments spaced a month apart. The website is made up of deoxycholic acid, a naturally occurring molecule that helps the body break down fat.
The drug is in late-stage clinical trials, and is yet to be approved by the FDA. The injections have been tested on over 1,600 patients, with over 90% reporting a long term reduction of fat under the chin.
The amount of treatments needed will depend on each individual patient, but on average, patients in the clinical trials had between 4 and 6.
The company say the drug was tolerated well by most patients, and that the most common side effects experienced were pain around the treatment area, numbness, bruising, swelling and redness.
The FDA is set to complete its review of the drug on the 13th May.
